• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

利妥昔单抗治疗寻常型天疱疮：一例报告

Pemphigus vulgaris Treated With Rituximab: A Case Report.

作者信息

Faria Guilherme N, Fernandes Pedro, Coelho Diana, Franco Susana, Sardinha Tiago, Esteves Tiago

机构信息

Famiy Medicine, Centro de Saúde do Porto da Cruz, Serviço de Saúde da Região Autónoma da Madeira (SESARAM), Funchal, PRT.

Dermatology, Hospital Dr. Nélio Mendonça, Serviço de Saúde da Região Autónoma da Madeira (SESARAM), Funchal, PRT.

出版信息

Cureus. 2024 Nov 26;16(11):e74511. doi: 10.7759/cureus.74511. eCollection 2024 Nov.

DOI:10.7759/cureus.74511
PMID:39726523
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11670898/
Abstract

This case report highlights the efficacy of rituximab (RTX), a monoclonal antibody that targets B-lymphocytes, in the treatment of severe pemphigus vulgaris (PV) that was unresponsive to multiple conventional therapies. A 44-year-old female presented with mucocutaneous lesions that had been progressing for 12 months, with a Pemphigus Disease and Area Index (PDAI) total activity score of 66, indicating severe disease. The patient received two infusions of RTX two weeks apart, without complications. Complete remission of the lesions was observed after four months of follow-up. The successful outcome of this case report reinforces RTX as a first-line treatment option in severe PV cases, although its feasibility should still be considered. It is important to note that RTX treatment may have limitations due to its high cost, potential for immunosuppression, and relatively high relapse rate after treatment cessation. This case report provides insights into the potential use of RTX in the treatment of moderate to severe PV and emphasizes the need for further research to evaluate its efficacy, safety, and long-term outcomes.

摘要

本病例报告强调了利妥昔单抗（RTX）——一种靶向B淋巴细胞的单克隆抗体——在治疗对多种传统疗法均无反应的重度寻常型天疱疮（PV）中的疗效。一名44岁女性出现黏膜皮肤病变，病程已达12个月，天疱疮疾病与面积指数（PDAI）总活动评分为66，表明病情严重。该患者每隔两周接受两次RTX输注，未出现并发症。随访四个月后观察到病变完全缓解。本病例报告的成功结果强化了RTX作为重度PV病例一线治疗选择的地位，尽管其可行性仍应予以考虑。需要注意的是，RTX治疗可能存在局限性，因其成本高昂、有免疫抑制的可能性，且在治疗停止后复发率相对较高。本病例报告为RTX在中度至重度PV治疗中的潜在应用提供了见解，并强调需要进一步研究以评估其疗效、安全性和长期结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e48/11670898/27de5e34e09a/cureus-0016-00000074511-i09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e48/11670898/83a906c6aac0/cureus-0016-00000074511-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e48/11670898/47ecf204c937/cureus-0016-00000074511-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e48/11670898/05106efee130/cureus-0016-00000074511-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e48/11670898/bc416201050b/cureus-0016-00000074511-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e48/11670898/02de50acee42/cureus-0016-00000074511-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e48/11670898/6eea450cdaab/cureus-0016-00000074511-i06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e48/11670898/ca660b28a897/cureus-0016-00000074511-i07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e48/11670898/7c50f4e87134/cureus-0016-00000074511-i08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e48/11670898/27de5e34e09a/cureus-0016-00000074511-i09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e48/11670898/83a906c6aac0/cureus-0016-00000074511-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e48/11670898/47ecf204c937/cureus-0016-00000074511-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e48/11670898/05106efee130/cureus-0016-00000074511-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e48/11670898/bc416201050b/cureus-0016-00000074511-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e48/11670898/02de50acee42/cureus-0016-00000074511-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e48/11670898/6eea450cdaab/cureus-0016-00000074511-i06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e48/11670898/ca660b28a897/cureus-0016-00000074511-i07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e48/11670898/7c50f4e87134/cureus-0016-00000074511-i08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e48/11670898/27de5e34e09a/cureus-0016-00000074511-i09.jpg

相似文献

1
Pemphigus vulgaris Treated With Rituximab: A Case Report.利妥昔单抗治疗寻常型天疱疮：一例报告
Cureus. 2024 Nov 26;16(11):e74511. doi: 10.7759/cureus.74511. eCollection 2024 Nov.
2
Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study.生物类似药利妥昔单抗治疗寻常型天疱疮患者的疗效和安全性：一项前瞻性观察研究。
J Dermatolog Treat. 2021 Feb;32(1):33-40. doi: 10.1080/09546634.2019.1617831. Epub 2019 May 28.
3
The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study.低剂量利妥昔单抗治疗寻常型天疱疮的疗效和安全性：一项队列研究。
J Dermatolog Treat. 2024 Dec;35(1):2302071. doi: 10.1080/09546634.2024.2302071. Epub 2024 Jan 22.
4
Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-naïve and previously treated patients with pemphigus vulgaris after receiving rituximab.在接受利妥昔单抗治疗的初治和既往治疗过的寻常型天疱疮患者中，使用传统和构象抗桥粒芯糖蛋白抗体进行短期临床和血清学随访。
Int J Womens Dermatol. 2019 Jun 7;5(5):372-377. doi: 10.1016/j.ijwd.2019.05.008. eCollection 2019 Dec.
5
Rituximab treatment in pemphigus vulgaris: effect on circulating Tregs.寻常型天疱疮的利妥昔单抗治疗：对循环 Tregs 的影响。
Arch Dermatol Res. 2017 Sep;309(7):551-556. doi: 10.1007/s00403-017-1754-z. Epub 2017 Jun 19.
6
The emergence of circulating activated autoreactive desmoglein 3-specific follicular regulatory T cells is associated with long-term efficacy of rituximab in patients with pemphigus vulgaris.循环激活的自身反应性桥粒芯糖蛋白 3 特异性滤泡调节性 T 细胞的出现与利妥昔单抗治疗寻常型天疱疮患者的长期疗效相关。
Br J Dermatol. 2024 Sep 18;191(4):605-615. doi: 10.1093/bjd/ljae220.
7
The use of rituximab as an adjuvant in the treatment of oral pemphigus vulgaris.利妥昔单抗作为辅助治疗寻常型天疱疮的应用。
J Oral Pathol Med. 2020 Jan;49(1):91-95. doi: 10.1111/jop.12951. Epub 2019 Sep 6.
8
Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration.利妥昔单抗治疗寻常型天疱疮和落叶型天疱疮的临床疗效评价。
Dermatol Ther. 2021 Jan;34(1):e14633. doi: 10.1111/dth.14633. Epub 2020 Dec 15.
9
SARS-CoV-2 Infection in Pemphigus Vulgaris Two Weeks after Rituximab Therapy with Total Recovery: A Case Report.天疱疮患者利妥昔单抗治疗 2 周后发生 SARS-CoV-2 感染并完全康复：1 例病例报告。
Acta Dermatovenerol Croat. 2023 Dec;31(3):156-157.
10
Rituximab in Pemphigus - An Observational Study from a Tertiary Care Center of North India.利妥昔单抗治疗天疱疮——来自印度北部一家三级医疗中心的观察性研究
Indian Dermatol Online J. 2022 Sep 5;13(5):620-624. doi: 10.4103/idoj.idoj_170_22. eCollection 2022 Sep-Oct.

本文引用的文献

1
Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).欧洲皮肤病学会和性病学会更新的 S2K 大疱性类天疱疮管理指南。
J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1689-1704. doi: 10.1111/jdv.18220. Epub 2022 Jun 29.
2
British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017.英国皮肤科医师协会2017年寻常型天疱疮管理指南
Br J Dermatol. 2017 Nov;177(5):1170-1201. doi: 10.1111/bjd.15930.
3
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
一线利妥昔单抗联合短期泼尼松与单独泼尼松治疗天疱疮（Ritux 3）：一项前瞻性、多中心、平行组、开放标签随机试验。
Lancet. 2017 May 20;389(10083):2031-2040. doi: 10.1016/S0140-6736(17)30070-3. Epub 2017 Mar 22.
4
Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens.利妥昔单抗治疗天疱疮的疗效：不同方案的系统评价和荟萃分析
Acta Derm Venereol. 2015 Nov;95(8):928-32. doi: 10.2340/00015555-2116.
5
Pemphigus vulgaris: an evidence-based treatment update.寻常型天疱疮：基于证据的治疗更新。
Drugs. 2015 Feb;75(3):271-84. doi: 10.1007/s40265-015-0353-6.
6
Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis).天疱疮组（寻常型、落叶型、增殖型、疱疹样型、巴西型）。
Clin Dermatol. 2011 Jul-Aug;29(4):432-6. doi: 10.1016/j.clindermatol.2011.01.013.
7
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.天疱疮疾病、终点指标及治疗反应定义的共识声明。
J Am Acad Dermatol. 2008 Jun;58(6):1043-6. doi: 10.1016/j.jaad.2008.01.012. Epub 2008 Mar 14.